GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece). These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.
Western Galilee Medical Center, based in Nahariya, Israel, is a leading institution in the study of oxidative stress. Dr. Shifra Sela and Dr. Batya Kristal will serve as the principle investigators studying oxidation-reduction potential in hypertension and hemodialysis. Both researchers have studied oxidative stress for over 20 years, and their work has been extensively published.The University of Thessaly, comprising faculties of Medicine, Biochemistry and Biotechnology in Larissa, Greece, is an established institution supported by University Hospital of Larissa and focused on patient care and research, including the study of oxidative stress in critical conditions. Dr. Maria Karapetsa, Dr. Epaminondas Zakynthinos, Dr. Dimitrios Kouretas, and Dr. Dimitrios Stagos will serve as the principle investigators studying oxidation-reduction potential in sepsis and physical exertion. All researchers have multiple publications to their credit. "We are pleased to be partnering with Western Galilee Medical Center and the University of Thessaly on these important research projects," said Josh Disbrow, Chief Executive Officer of Luoxis. "Luoxis and these prominent research teams share a strong interest in advancing the study of oxidative stress, and we believe incorporating oxidation-reduction potential measurements into current diagnostic practice will significantly advance assessment of human oxidative stress in prevalent and challenging patient populations." Both research centers, in collaboration with Dr. David Bar-Or, Ampio and Luoxis Chief Scientific Officer, expect to publish the results of their research in peer-reviewed publications following completion of the studies.